Cargando…

MON-001 Peripartum Sertraline (Zoloft®) Increases Pup Mortality Immediately Postpartum

Peripartum and postpartum depression can be detrimental to both the mother and the developing child. Use of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), is common during the peripartal period and SSRIs have been the leading prescribed antidepressant to treat maternal dep...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheftel, Celeste, Sartori, Luma C, Manuel, Robbie, Fricke, Hannah, Bell, Autumn, Mulvenna, Elizabeth, Hernandez, Laura L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207425/
http://dx.doi.org/10.1210/jendso/bvaa046.1840
_version_ 1783530602261118976
author Sheftel, Celeste
Sartori, Luma C
Manuel, Robbie
Fricke, Hannah
Bell, Autumn
Mulvenna, Elizabeth
Hernandez, Laura L
author_facet Sheftel, Celeste
Sartori, Luma C
Manuel, Robbie
Fricke, Hannah
Bell, Autumn
Mulvenna, Elizabeth
Hernandez, Laura L
author_sort Sheftel, Celeste
collection PubMed
description Peripartum and postpartum depression can be detrimental to both the mother and the developing child. Use of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), is common during the peripartal period and SSRIs have been the leading prescribed antidepressant to treat maternal depression. One of the most commonly prescribed SSRIs is sertraline (Zoloft®) because of the limited fetal teratogenic effects observed, unlike maternal paroxetine (Paxil®) usage which can manifest in fetal cardiovascular defects. Fluoxetine (Prozac®), like sertraline, has previously been shown to have limited teratogenic effects, however, we have shown treatment with fluoxetine for the entire period of pregnancy and lactation in mice compromises pup bones at weaning resulting in decreased long bone length and head circumference. Furthermore, maternal fluoxetine usage results in a sustained reduction in maternal bone mineral density post weaning, which may lead to long-term osteopenia, putting the mother at risk for bone-related disorders later in life. We hypothesized sertraline, like fluoxetine, will compromise maternal bone postpartum and fetal bone development at weaning. Treatment with sertraline in C57BL/6 dams throughout pregnancy and lactation reduced litter size (5.4 pups/dam) and increased pup mortality during the first 24 hours postpartum (20% dead pups/litter) compared to controls (6.8 pups/dam, 5% dead pups/litter, respectively; P < 0.018). Maternal calcium transporters (Orai1 and Serca2) were downregulated in the mammary gland in sertraline-treated dams on day 21 of lactation (P < 0.0032). Together, our data suggests in utero pharmacological exposure to sertraline may induce a failure to thrive in the pups and alters calcium metabolism in the dam. SSRI exposure during pregnancy and lactation may adversely affect the developing neonate(s) as well as have lasting impacts on the mother.
format Online
Article
Text
id pubmed-7207425
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72074252020-05-13 MON-001 Peripartum Sertraline (Zoloft®) Increases Pup Mortality Immediately Postpartum Sheftel, Celeste Sartori, Luma C Manuel, Robbie Fricke, Hannah Bell, Autumn Mulvenna, Elizabeth Hernandez, Laura L J Endocr Soc Reproductive Endocrinology Peripartum and postpartum depression can be detrimental to both the mother and the developing child. Use of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), is common during the peripartal period and SSRIs have been the leading prescribed antidepressant to treat maternal depression. One of the most commonly prescribed SSRIs is sertraline (Zoloft®) because of the limited fetal teratogenic effects observed, unlike maternal paroxetine (Paxil®) usage which can manifest in fetal cardiovascular defects. Fluoxetine (Prozac®), like sertraline, has previously been shown to have limited teratogenic effects, however, we have shown treatment with fluoxetine for the entire period of pregnancy and lactation in mice compromises pup bones at weaning resulting in decreased long bone length and head circumference. Furthermore, maternal fluoxetine usage results in a sustained reduction in maternal bone mineral density post weaning, which may lead to long-term osteopenia, putting the mother at risk for bone-related disorders later in life. We hypothesized sertraline, like fluoxetine, will compromise maternal bone postpartum and fetal bone development at weaning. Treatment with sertraline in C57BL/6 dams throughout pregnancy and lactation reduced litter size (5.4 pups/dam) and increased pup mortality during the first 24 hours postpartum (20% dead pups/litter) compared to controls (6.8 pups/dam, 5% dead pups/litter, respectively; P < 0.018). Maternal calcium transporters (Orai1 and Serca2) were downregulated in the mammary gland in sertraline-treated dams on day 21 of lactation (P < 0.0032). Together, our data suggests in utero pharmacological exposure to sertraline may induce a failure to thrive in the pups and alters calcium metabolism in the dam. SSRI exposure during pregnancy and lactation may adversely affect the developing neonate(s) as well as have lasting impacts on the mother. Oxford University Press 2020-05-08 /pmc/articles/PMC7207425/ http://dx.doi.org/10.1210/jendso/bvaa046.1840 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Reproductive Endocrinology
Sheftel, Celeste
Sartori, Luma C
Manuel, Robbie
Fricke, Hannah
Bell, Autumn
Mulvenna, Elizabeth
Hernandez, Laura L
MON-001 Peripartum Sertraline (Zoloft®) Increases Pup Mortality Immediately Postpartum
title MON-001 Peripartum Sertraline (Zoloft®) Increases Pup Mortality Immediately Postpartum
title_full MON-001 Peripartum Sertraline (Zoloft®) Increases Pup Mortality Immediately Postpartum
title_fullStr MON-001 Peripartum Sertraline (Zoloft®) Increases Pup Mortality Immediately Postpartum
title_full_unstemmed MON-001 Peripartum Sertraline (Zoloft®) Increases Pup Mortality Immediately Postpartum
title_short MON-001 Peripartum Sertraline (Zoloft®) Increases Pup Mortality Immediately Postpartum
title_sort mon-001 peripartum sertraline (zoloft®) increases pup mortality immediately postpartum
topic Reproductive Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207425/
http://dx.doi.org/10.1210/jendso/bvaa046.1840
work_keys_str_mv AT sheftelceleste mon001peripartumsertralinezoloftincreasespupmortalityimmediatelypostpartum
AT sartorilumac mon001peripartumsertralinezoloftincreasespupmortalityimmediatelypostpartum
AT manuelrobbie mon001peripartumsertralinezoloftincreasespupmortalityimmediatelypostpartum
AT frickehannah mon001peripartumsertralinezoloftincreasespupmortalityimmediatelypostpartum
AT bellautumn mon001peripartumsertralinezoloftincreasespupmortalityimmediatelypostpartum
AT mulvennaelizabeth mon001peripartumsertralinezoloftincreasespupmortalityimmediatelypostpartum
AT hernandezlaural mon001peripartumsertralinezoloftincreasespupmortalityimmediatelypostpartum